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Abstract Previous studies of the occurrence of interstitial
lung disease (ILD) in undifferentiated connective tissue
diseases (UCTD) were conducted in patients admitted to
Respiratory Medicine Units. The aim of the present pro-
spective study was to investigate lung involvement in
UCTD patients admitted to a Rheumatology Unit. Eighty-
one consecutive UCTD patients were enrolled in the study.
Each patient underwent history and physical examination,
routine laboratory investigations, antinuclear antibody
(ANA) profiling, B-mode echocardiography, and lung func-
tion study according to previously reported methods. Lung
high resolution computed tomography (HRCT) was per-
formed in patients who provided informed consent. Six
patients (7.4%) had a history of grade II dyspnea. Three
of them had a DLCO ranging from 42 to 55% of the
predicted value; and a HRCT-documented ILD with a
non-specific interstitial pneumonia (NSIP) pattern.
Symptoms in the other three patients were due to cardiac
disease. None of the 75 asymptomatic patients, had rele-
vant findings at physical examination, 26/75 had a DLCO
<80% (<70% in 10 cases). Of these, 3 of the 30 patients
who underwent lung HRCT were affected by NSIP-ILD.
Six of the 81 enrolled were affected by ILD, which was
symptomatic in three patients. A higher percentage of pa-
tients had a reduced DLCO. The latter finding may reflect
a preradiographic ILD or a preechocardiographic pulmo-
nary vascular disease.
Keywords Interstitial lung disease . Lung high resolution
computed tomography . Undifferentiated connective tissue
diseases
Introduction
Interstitial lung disease (ILD) represents a distinct manifesta-
tion of many connective tissue diseases (CTDs). Its preva-
lence is highest in Systemic Sclerosis (SSc), but it also occurs
in a significant percentage of patients with Mixed Connective
Tissue disease, Systemic Lupus Erythematosus, Sjögren’s
Syndrome, Polymyositis Dermatomyositis, and Rheumatoid
Arthritis [1, 2].
In recent years, various studies reported that some
ILD patients present features suggestive of an autoim-
mune origin even though they do not meet the classifi-
cation criteria for any major CTD. Such a condition has
been considered as ILD secondary to undifferentiated
CTD (UCTD) [3, 4] and otherwise referred to as lung
dominant CTD [5], autoimmune featured ILD (AIF-ILD)
[6], and interstitial pneumonia with autoimmune features
(IPAF) [7].
Previous studies of ILD secondary to UCTD were con-
ducted in patients admitted to Respiratory Medicine Units
for evaluation of an ILD and investigated for features con-
sistent with either a major CTD or a UCTD. The aim of
our study was to investigate lung involvement in consecu-
tive patients with Bstable^ UCTD admitted to a
Rheumatology Unit.
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Materials and methods
Patients
UCTDpatients consecutively admitted to the outpatient clinic of
the Rheumatology Unit of the University of Campania BLuigi
Vanvitelli^ (previously named Second University of Naples)
from 1st January 2013 to 31st December 2015 were enrolled
in the study, after giving their written informed consent.
UCTD was diagnosed according to Mosca et al. [8] and
Doria et al. [9]. Briefly, patients had to (a) present signs and
symptoms suggestive of a CTD without fulfilling the criteria
of any definite CTD [8]; (b) be antinuclear antibodies (ANA)
positive; (c) do not have either any CTD marker autoantibody
(i.e., anti-dsDNA, anti-Sm, anti-ribosomal P protein, anti-Scl-
70, anticentromere, anti-La/SSB, anti-Jo1, anti-Mi-2) or any
manifestation distinctive of any major CTD (i.e., malar rash,
subacute CLE, chronic CLE, skin sclerosis, heliotrope rash,
Gottron’s plaques, erosive arthritis, alopecia) [9]; and (d) have
a disease duration as assessed from the onset of the 1st
symptom/sign ≥3 years. Therefore, our patients were affected
by Bstable UCTD,^ according to Mosca et al. [10].
Routine assessment
According to standard clinical practice and to ensure a correct
classification, each patient with a suspected UCTD underwent a
detailed history and physical examination to identify: (I) any of
the above-listed exclusion criteria [8, 9]; (II) symptoms/signs of
ILD, namely dyspnea, graded according to the New York Heart
Association, and bibasilar crackles; (III) routine laboratory in-
vestigations, namely, blood cell count, urinalysis, blood urea
nitrogen, serum creatinine, alanine aminotransferase, aspartate
aminotransferase, erythrosedimentation rate, serum protein elec-
trophoresis, serum C3 and C4 concentration; (IV) nailfold
videocapillaroscopy (NVC), (V) ANA screening and profiling;
and (VI) B-mode echocardiography and lung function testing.
Autoantibody profile assessment
Autoantibodies were investigated in sera collected at the first
visit, stored at −20 °C and heated at 56 °C for 30min before
testing. ANA and ACAwere determined by indirect immuno-
fluorescence on HEp-2 cells (Astra srl, Pavone Canavese,
Italy), using fluorescent anti-human gammaglobulin as conju-
gate, and a 1:160 serum dilution as cut-off value. Anti-Scl-70,
anti-SSA, anti-SSB, anti-Sm, anti-Jo1, and anti-U1RNP were
identified with commercially available ELISA kits (Chematil
srl, Angri, Italy), using 25 U/ml as cut-off value. Anti-RNA
polymerase III, anti-fibrillarin, and anti-Pm-Scl were investi-
gated by EliAVarelisa Phadia test (Germany) using 150 U/ml
as cut-off value. Anti-Th/To were investigated by western
blotting technique (Arnika srl, Milan, Italy). Anti-DNA ds
antibodies were identified by IIF on Crithidia luciliae at a
serum dilution of 1:10 (Astra srl) [11].
Nailfold videocapillaroscopy assessment
Patients were investigated for typical microvascular alter-
ations (megacapillaries and/or avascular areas) by NCV. It
was carried out while the patients were seated with their hands
positioned at heart level, and at a room temperature of 22–
25 °C. A drop of immersion oil was applied to the nailfold to
increase the translucency of the keratin layer. All the fingers
were examined by the same physician (R.I.) who is experi-
enced in NCV using a videocapillaroscope (Videocap 25-DS
Medica; Freiburg, Germany) with optical probes of ×200. The
degree of capillary enlargement on a scale of 0–3 and capillary
loss (grades A–D)were considered.Megacapillaries (capillary
enlargement ≥2) and/or avascular areas (capillary loss grade
≥C) were considered a scleroderma pattern [12].
Assessment of internal organ involvement
All patients underwent B-mode echocardiography and lung
function study. Echocardiographic examination was performed
as described elsewhere [13]. Pulmonary function tests including
forced vital capacity (FVC), total lung capacity (TLC), forced
expiratory volume 1/FVC (FEV1/FVC), and diffusing capacity
for carbon monoxide (DLCO), expressed as percentages of pre-
dicted values based on age, sex and height and corrected for
hemoglobin level, were performed according to techniques ap-
proved by the American Thoracic Society (ATS) [14]. The per-
centage predicted DLCO value reported was the average of at
least two acceptable tests meeting the reproducibility require-
ments of ATS [15]. The detection of either a DLCO or a FVC
<80% of the respective predicted values in the absence of
smoking, obstructive lung disease, and/or cardiac involvement
was considered indicative of possible ILD [16–19].
Patients giving additional consent underwent a high resolu-
tion computed tomography of lungs (Lung HRCT). Chest
HRCT images were obtained with 1-mm collimation and 10-
mm intervals at maximal end- inspiratory phase with the patient
in a supine position using a high spatial frequency algorithm. If
needed, prone scans were added to distinguish gravity-related
changes from structural abnormalities. According to Fischer
et al. [19], the presence of a non-specific interstitial pneumonia
(NSIP), usual interstitial pneumonia (UIP), organizing pneu-
monia (OP), and lymphoid interstitial pneumonia (LIP) were
considered consistent with a diagnosis of ILD.
Follow-up
Each patient was annually investigated for clinical manifesta-
tions, laboratory findings and lung function. Patients with a
baseline HRCT-detected ILD and those experiencing
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deterioration in lung function at spirometry were invited to
undergo HRCT and B-mode echocardiography with estima-
tion of pulmonary systolic arterial pressure.
Statistical analysis
We used the SPSS for Windows software (version 16.0) for
statistical analysis. Categorical data were analyzed by contingen-
cy table (chi square). A p value <0.05was considered significant.
The study was approved by the ethics committee of the
University of Campania BLuigi Vanvitelli^.
Results
Lung findings at baseline
Eighty-one consecutive Caucasian UCTD patients were en-
rolled in this study. Most patients were female (90.1%), and
the median age was 40 years (from 33 to 48); the median
disease duration was 6 years (from 5 to 11).
Table 1 summarizes the main demographic, clinical and lab-
oratory features of the patients enrolled. The most frequent clin-
ical manifestations related to CTD were arthralgias/arthritis
(70.3%), asthenia (51.8%), Raynaud’s phenomenon (49.3%),
myalgias (46.9%), and ocular and/or oral dryness (43.2%).
Six patients presented effort dyspnea, all of them grade II.
Three of these patients had bibasilar crackles and a DLCO
value of 42, 44, and 55%, respectively. One had a mild restric-
tive pattern of the volume flow curve namely, TLC <80%,
FVC >80% of the predicted value and FEV1/FVC >70%.
The other two patients had a normal volume flow curve:
TLC and FVC >80% and FEV1/FVC >70% of the predicted
values. All three presented a bibasilar NSIP pattern at lung
HRCT. These patients, accounting for 3.7% of our series, were
considered to have symptomatic ILD secondary to UCTD.
The other three dyspnoic patients did not present either basilar
crackles or ILD findings at HRCT or a DLCO <70% of the
predicted value and were affected by hypertensive cardiomy-
opathy (arterial hypertension, cardiac hypertrophy, and dia-
stolic dysfunction), which accounted for effort dyspnea.
Of the remaining 75 UCTD asymptomatic patients, none
had relevant findings at physical examination, all had TLC
and FVC >80% of the predicted values; one of them presented
a mild obstructive pattern of the volume flow curve and
FEV1/FVC <70%. Twenty-six patients had a DLCO <80%,
which was <70% in 10 cases. Sixteen of these 26 patients had
findings that could account for the reduced DLCO (11 were
smokers, 4 were affected by pulmonary vascular disease de-
tected by echocardiography, and 1 had chronic obstructive
pulmonary disease). The remaining 10 did not present any
feature that could explain the reduced DLCO.
In summary, a definite, i.e., HRCT-documented ILD was
identified in 6 out of 81 consecutive UCTD patients (7.4%), 3
of whom had a DLCO <70% as the only altered physiologic
parameter, and only one had a DLCO <70% and TLC <80%.
On the other hand, an altered DLCO, unexplained by any
other cause, was detected in 10 further patients, 2 of whom
presented a DLCO value <70%.
Relationships between lung alterations and other disease
findings
Statistical analysis did not reveal any relationships between
lung involvement features, i.e., HRCT-documented ILD or
Table 1 Main baseline demographic and clinical features of the 81
UCTD patients enrolled
Demographic and clinical features
Female, n (%) 73 (90.1)
Age, yrs, median (range) 40 (33–48)
Disease duration from the first
symptom, yrs, median (range)
6 (5–11)
Smokers 20 (24.6%)
Clinical features
Arthralgias/arthritis, n (%) 57(70.3)
Raynaud’s phenomenon, n (%) 40 (49.3)
Oral and/or ocular dryness, n (%) 35 (43.2)
Carpal tunnel syndrome, n (%) 21 (25.9)
Bibasilar crackles 3 (3.7%)
Estimated sPAP >40 mmHg 1 (1.2%)
Impaired left ventricular function 24 (29.6%)
Dyspnea at presentation, n (%) 6 (7.4)
Laboratory features
Antinuclear positivity, n (%) 81 (100%)
Anti-SSA positive, n (%) 16 (19.7)
ESR ≥30 mm/h and/or CRP >1 mg/dl, n (%) 14 (17.2)
Hypocomplementemia, n (%) 10 (12.3)
Leucopenia, n (%) 4 (4.9)
Lymphopenia, n (%) 1 (1.2)
Thrombocytopenia, n (%) 1 (1.2)
Physiology and imaging
FVC <80%, n (%) 1 (1.2)
TLC <80%, n (%) 1 (1.2)
FEV1/FVC <70% 1 (1.2%)
DLCO <80%, n (%) 31 (38.2)
DLCO <70%, n (%) 13 (16)
ILD at HRCT, n (%) 6 (7.4)
yrs years, ESR erythrocyte sedimentation rate, CRP C-reactive protein,
FVC forced vital capacity, TLC total lung capacity, FEV1/FVC expiratory
volume 1/FVC, DLCO diffusing capacity for carbon monoxide, ILD in-
terstitial lung disease, HRCT high resolution computed tomography
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isolated DLCO, and any disease feature including disease du-
ration, Raynaud’s phenomenon, anti-SSA positivity and al-
tered inflammation indices.
Follow-up evaluation
After a follow-up ranging from 1 to 2 years, the three patients
with ILD in the symptomatic group still presented normal
FVC values, moderate reduction of DLCO values, and a
NSIP pattern at HRCT. They were treated with azathioprine,
which resulted in stabilization of lung function (i.e., ΔFVC
and ΔDLCO <10%) and no progression of the radiologic
extension. Seven of the 10 UCTD asymptomatic patients with
an aberrant DLCO values unexplained by any other cause at
baseline remained stable and three improved (i.e., increased
>15% of the basal value).
Discussion
Kinder et al. first investigated 75 ILD patients admitted to a
ILD Center, 28 of whom had features compatible with a diag-
nosis of UCTD. They found that a ground-glass pattern con-
sistent with an NSIP was more frequent in UCTD-ILD than in
idiopathic ILD, and that 88% of the 75 patients found to have
a ILD with a NSIP pattern at lung HRCT, had autoimmune
features consistent with a diagnosis of UCTD [3].
Suda et al. [20] compared the lung features of 22 patients
affected by UCTD-NSIP with those of 25 patients affected by
primary NSIP and found a female preponderance and a pre-
dominantly lymphocyte infiltration as detected by bronchoal-
veolar lavage analysis in women.
We invest igated UCTD patients admit ted to a
Rheumatology Unit. Our patients presented lung symptoms
and signs and physiologic and imaging findings milder than
those detected in patients admitted to Pneumology Units
[3–7]. When asked, only 6/75 patients declared grade II effort
dyspnoea. Of these, only three were affected by ILD as
witnessed by an NSIP pattern at HRCT and characterized by
a reduction of DLCO in all three cases.
Of the 75 remaining patients, HRCT, carried out in 30,
revealed ILD in 3 other patients in whom FVC was >80% of
the predicted value in all and DLCO was <70% in one case
only. Therefore, ILD was identified in 3 out 6 symptomatic
patients and in 3 of 75 asymptomatic patients for a prevalence
of 7.4%.
Unexpectedly, we found a decreased DLCO unexplained
by smoking or obstructive pulmonary disease or clinically or
echocardiographically detected cardiac or pulmonary vascular
disease in 10 other patients (12.3%).
DLCO does not strictly reflect ILD since it can be influ-
enced by vascular pulmonary disease, smoking and obstruc-
tive disease [15]. Nevertheless, it is noteworthy that 20/73
patients with SSc (27%) admitted to Pittsburgh Unit with an
isolated reduction of DLCO developed a restrictive pattern
during the follow-up and, more importantly, 22% of them
already presented pulmonary fibrosis as detected by chest x-
ray at baseline and 43% had this feature at a 5.4-year follow-
up [16]. Notably, DLCO has been recently demonstrated to
provide the best overall estimate of HRCT-measured SSc-ILD
disease in the absence of pulmonary hypertension [21]. In that
context, we detected a preradiographic alveolitis in 13/29 pa-
tients with SSc, presenting with a reduced DLCO as the only
altered parameter and investigated by bronchoalveolar lavage
analysis [22]. Given the differences in the evolution between
SSc-ILD [21–24] and UCTD-ILD [2, 4] and because data
from SSc patients cannot be estrapolated to UCTD, we treated
our patients with azathioprine. Indeed, the 3 symptomatic pa-
tients with UCTD-ILD responded to azathioprine therapy,
whereas DLCO values remained stable or improved in the
10 asymptomatic patients with abnormal values at baseline
in the absence of CT-detected ILD.
Recently, Ferri et al. [25] compared demographic and clin-
ical data of patients with IPF and IPAF admitted to a
Respiratory Unit with those of UCTD patients attending a
Rheumatology Unit and hypothesized that IPAF and UCTD
might be two clinical variants of the same systemic autoim-
mune disorder, and that the difference in the prevalence of
ILD might at least in part due to selection bias between pa-
tients referred to different specialties.
Nosographic controversies are still present in this topic
point of view. Nevertheless, from a clinical point of view,
our data suggest that lung involvement be investigated in pa-
tients with UCTD admitted to Rheumatology Units. From a
pathophysiologic point of view, the finding of an isolated re-
duction of DLCO should be investigated to determine its or-
igin (vascular, alveolar wall infiltration), clinical impact and
treatment, if necessary.
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